# AstraZeneca says the recommendation follows late?stage trial results showing the combination helps delay disease progression.

*biotech · news · 2026-05-01 · MarketScreener*

## Key points

- The FDA advisory committee recommended Truqap's benefit-risk profile for PTEN-deficient prostate cancer.
- Truqap, combined with abiraterone and hormone therapy, delays disease progression in late-stage trials.
- This is the first targeted treatment shown to benefit PTEN-deficient metastatic hormone-sensitive prostate cancer.
- The FDA's decision follows earlier acceptance of AstraZeneca's application for Truqap.

**Companies:** AstraZeneca PLC
**Countries:** United Kingdom, United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/astrazeneca-gets-fda-panel-nod-for-truqap-in-prostate-cancer-ce7f58d8d08aff23)

---

Canonical: https://newsio.io/n/e674eb5c-16f3-4f9f-8f11-87253f73e6de/astrazeneca-says-the-recommendation-follows-latestage-trial-results-showing-the
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works